Therapeutic targeting of casein kinase 1δ in breast cancer

Laura H. Rosenberg, Marie Lafitte, Victor Quereda, Wayne Grant, Weimin Chen, Mathieu Bibian, Yoshihiko Noguchi, Mohammad Fallahi, Chunying Yang, Jenny C. Chang, William R. Roush, John L. Cleveland, Derek R. Duckett

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Identification of specific drivers of human cancer is required to instruct the development of targeted therapeutics. We demonstrate that CSNK1D is amplified and/or overexpressed in human breast tumors and that casein kinase 1d (CK1δ) is a vulnerability of human breast cancer subtypes overexpressing this kinase. Specifically, selective knockdown of CK1δ, or treatment with a highly selective and potent CK1δ inhibitor, triggers apoptosis of CK1δ-expressing breast tumor cells ex vivo, tumor regression in orthotopic models of triple-negative breast cancer, including patient-derived xenografts, and tumor growth inhibition in human epidermal growth factor receptor 2-positive (HER2+) breast cancer models. We also show that Wnt/δ-catenin signaling is a hallmark of human tumors overexpressing CK1δ, that disabling CK1δ blocks nuclear accumulation of β-catenin and T cell factor transcriptional activity, and that constitutively active δ-catenin overrides the effects of inhibition or silencing of CK1δ. Thus, CK1δ inhibition represents a promising strategy for targeted treatment in human breast cancer with Wnt/δ-catenin involvement.

Original languageEnglish (US)
Article number318ra202
JournalScience translational medicine
Issue number318
StatePublished - Dec 16 2015

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Therapeutic targeting of casein kinase 1δ in breast cancer'. Together they form a unique fingerprint.

Cite this